1. Home
  2. AGX vs ADPT Comparison

AGX vs ADPT Comparison

Compare AGX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Argan Inc.

AGX

Argan Inc.

SELL

Current Price

$348.80

Market Cap

5.6B

ML Signal

SELL

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

SELL

Current Price

$24.17

Market Cap

4.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AGX
ADPT
Founded
1961
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
4.5B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
AGX
ADPT
Price
$348.80
$24.17
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
★ $570.50
$29.81
AVG Volume (30 Days)
353.9K
★ 2.3M
Earning Date
09-02-2026
11-04-2026
Dividend Yield
★ 0.54%
N/A
EPS Growth
58.37
★ 63.89
EPS
★ 7.01
N/A
Revenue
★ $944,606,000.00
$276,976,000.00
Revenue This Year
$48.32
$5.94
Revenue Next Year
$20.43
$22.42
P/E Ratio
$52.32
★ N/A
Revenue Growth
8.06
★ 54.77
52 Week Low
$257.62
$12.00
52 Week High
$805.75
$30.74

Technical Indicators

Market Signals
Indicator
AGX
ADPT
Relative Strength Index (RSI) 33.95 38.18
Support Level $333.39 $23.73
Resistance Level $447.21 $26.51
Average True Range (ATR) 17.71 1.45
MACD 1.18 -0.48
Stochastic Oscillator 5.99 4.79

Price Performance

Historical Comparison
AGX
ADPT

About AGX Argan Inc.

Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: